Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants – FullText – Medical Cannabis and Cannabinoids 2023, Vol. 6, No. 1

Abstract

Introduction: Treatment with cannabis extracts for a variety of diseases has gained popularity. However, differences in herb-drug interaction potential of extracts from different plant sources are poorly understood. In this study, we provide a characterization of cannabis extracts prepared from four cannabis chemotypes and an in vitro assessment of their Cytochrome P450 (CYP)-mediated herb-drug interaction profiles. Methods: Plant extracts were either commercially obtained or prepared using ethanol as solvent, followed by overnight decarboxylation in a reflux condenser system. The extracts were characterized for their cannabinoid content using NMR and HPLC-PDA-ELSD-ESIMS. CYP inhibition studies with the cannabis extracts and pure cannabinoids (tetrahydrocannabinol [THC] and cannabidiol [CBD]) were performed using pooled, mixed gender human liver microsomes. Tolbutamide and testosterone were used as specific substrates to assess the inhibitory potential of the extracts on CYP2C9 and CYP3A4, and the coumarinic oral anticoagulants warfarin, phenprocoumon, and acenocoumarol were studied as model compounds since in vivo herb-drug interactions have previously been reported for this compound class. Results: In accordance with the plant chemotypes, two extracts were rich in THC and CBD (at different proportions); one extract contained mostly CBD and the other mostly cannabigerol (CBG). Residual amounts of the corresponding acids were found in all extracts. The extracts with a single major cannabinoid (CBD or CBG) inhibited CYP2C9- and CYP3A4-mediated metabolism stronger than the extracts containing both major cannabinoids (THC and CBD). The inhibition of CYP3A4 and CYP2C9 by the extract containing mostly CBD was comparable to their inhibition by pure CBD. In contrast, the inhibitory potency of extracts containing both THC and CBD did not correspond to the combined inhibitory potency of pure THC and CBD. Although being structural analogs, the three coumarin derivatives displayed major differences in their herb-drug interaction profiles with the cannabis extracts and the pure cannabinoids. Conclusion: Despite the fact that cannabinoids are the major components in ethanolic, decarboxylated cannabis extracts, it is difficult to foresee their herb-drug interaction profiles. Our in vitro data and the literature-based evidence on in vivo interactions indicate that cannabis extracts should be used cautiously when co-administered with drugs exhibiting a narrow therapeutic window, such as coumarinic anticoagulants, regardless of the cannabis chemotype used for extract preparation.

© 2023 The Author(s). Published by S. Karger AG, Basel

References



  1. Russo EB, Jiang H-E, Li X, Sutton A, Carboni A, del Bianco F, et al. Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot. 2008;59(15):4171–82.


  2. Adovasio JM, Soffer O, Klíma B. Upper Palaeolithic fibre technology: interlaced woven finds from Pavlov I, Czech Republic, c. 26,000 years ago. Antiquity. 1996;70(269):526–34.


  3. Crocq M-A. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–8.


  4. Kovalchuk I, Pellino M, Rigault P, van Velzen R, Ebersbach J, Ashnest JR, et al. The genomics of Cannabis and its close relatives. Annu Rev Plant Biol. 2020;71:713–39.


  5. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357–92.


  6. Radwan MM, Wanas AS, Chandra S, ElSohly MA. Natural cannabinoids of cannabis and methods of analysis. In: Chandra S, Lata H, ElSohly MA, editors. Cannabis sativa: bot biotechnol. Cham, Switzerland: Springer; 2017. p. 161–82.


  7. Brenneisen R. Chemistry and analysis of phytocannabinoids and other cannabis constituents. In: ElSohly MA, editor. Marijuana cannabinoids. Totowa (NJ): Humana Press; 2007. p. 17–49.


  8. Formato M, Crescente G, Scognamiglio M, Fiorentino A, Pecoraro MT, Piccolella S, et al. (‒)-Cannabidiolic acid, a still overlooked bioactive compound: an introductory review and preliminary research. Molecules. 2020;25(11):2638.


  9. Fankhauser M. Haschisch als Medikament. Zur Bedeutung vonCannabis sativa in der westlichen Medizin. Langnau, Switzerland: SGGP/SSHP; 2002.


  10. Fankhauser M. History of cannabis in Western medicine. In: Grotenhermen F, Russo E, editors. Cannabis cannabinoids pharmacol toxicol ther potential. Binghamton (NY): Haworth Press; 2002. p. 37–51.


  11. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623–39.


  12. Piomelli D, Mabou Tagne A. Endocannabinoid-based therapies. Annu Rev Pharmacol Toxicol. 2022;62:483–507.


  13. Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259.


  14. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472.


  15. Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, et al. Systematic review of systematic reviews for medical cannabinoids. Can Fam Physician. 2018;64(2):e78–94.


  16. Zürcher K, Dupont C, Weber P, Grunt S, Wilhelm I, Eigenmann DE, et al. Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland. Eur J Pediatr. 2022;181(1):335–47.


  17. Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15–16):730–6.


  18. Kocis PT, Vrana KE. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions. Med Cannabis Cannabinoids. 2020;3(1):61–73.


  19. Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332–8.


  20. Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Dispos. 2020;48(10):1008–17.


  21. Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization. AAPS J. 2021;23(4):91.


  22. Qian Y, Wang X, Markowitz JS. In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites. Drug Metab Dispos. 2019;47(5):465–72.


  23. Alsherbiny MA, Li CG. Medicinal cannabis-potential drug interactions. Medicines. 2018;6(1):3.


  24. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204–12.


  25. Choi YH, Hazekamp A, Peltenburg-Looman AMG, Frédérich M, Erkelens C, Lefeber AWM, et al. NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. Phytochem Anal. 2004;15(6):345–54.


  26. Barthlott I, Scharinger A, Golombek P, Kuballa T, Lachenmeier DW. A quantitative 1H NMR method for screening cannabinoids in CBD oils. Toxics. 2021;9(6):136.


  27. Thijssen HH, Flinois J-P, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000;28(11):1284–90.


  28. Busby WF, Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos. 1999;27(2):246–9.


  29. Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol. 2019;176(23):4537–47.


  30. Mandrioli M, Tura M, Scotti S, Gallina Toschi T. Fast detection of 10 cannabinoids by RP-HPLC-UV method in Cannabis sativa L. Molecules. 2019;24(11):2113.


  31. Martinenghi LD, Jønsson R, Lund T, Jenssen H. Isolation, purification, and antimicrobial characterization of cannabidiolic acid and cannabidiol from Cannabis sativa L. Biomolecules. 2020;10(6):900.


  32. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227–46.


  33. Kammerer B, Kahlich R, Ufer M, Schenkel A, Laufer S, Gleiter CH. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes. Anal Bioanal Chem. 2005;383(6):909–17.


  34. He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys. 1999;372:16–28.


  35. Kim S-Y, Kang J-Y, Hartman JH, Park S-H, Jones DR, Yun C-H, et al. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012;6(3):157–64.


  36. Hillig KW. Genetic evidence for speciation in cannabis (cannabaceae). Genet Resour Crop Evol. 2005;52(2):161–80.


  37. Small E, Cronquist A. A practical and natural taxonomy for Cannabis. Taxon. 1976;25(4):405–35.


  38. McPartland JM. Cannabis systematics at the levels of family, genus, and species. Cannabis Cannabinoid Res. 2018;3(1):203–12.


  39. Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, et al. Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J Nat Prod. 2016;79(2):324–31.


  40. Moreno-Sanz G, Ferreiro Vera C, Sánchez-Carnerero C, Nadal Roura X, Sánchez de Medina Baena V. Biological activity of Cannabis sativa L. extracts critically depends on solvent polarity and decarboxylation. Separations. 2020;7(4):56.


  41. Yamaori S, Maeda C, Yamamoto I, Watanabe K. Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol. 2011;29(2):117–24.


  42. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011;39(11):2049–56.


  43. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol. 2010;79(11):1691–8.


  44. Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019;124(1):28–31.


  45. Grayson L, Vines B, Nichol K, Szaflarski JP; UAB CBD Program. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2017;9:10–1.


  46. Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids. In: Nahas GG, Sutin KM, Harvey D, Agurell S, Pace N, Cancro R, editors. Marihuana med. Totowa (NJ): Humana Press; 1999. p. 91–103.


  47. Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of ∆9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther. 1990;255(2):624–30.


  48. Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019;85(9):1888–900.


  49. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–804.


  50. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.



Author Contacts

Matthias Hamburger, matthias.hamburger@unibas.ch


Article / Publication Details


Received: September 03, 2022
Accepted: November 28, 2022
Published online: February 08, 2023

Issue release date: January – December


Number of Print Pages: 11

Number of Figures: 5

Number of Tables: 1



eISSN: 2504-3889 (Online)


For additional information: https://www.karger.com/MCA


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *